GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.
| Revenue (TTM) | $21.64B |
| Gross Profit (TTM) | $8.50B |
| EBITDA | $3.60B |
| Operating Margin | 15.30% |
| Return on Equity | 20.00% |
| Return on Assets | 4.99% |
| Revenue/Share (TTM) | $47.69 |
| Book Value | $25.69 |
| Price-to-Book | 3.26 |
| Price-to-Sales (TTM) | 1.72 |
| EV/Revenue | 2.1 |
| EV/EBITDA | 11.87 |
| Quarterly Earnings Growth (YoY) | 39.00% |
| Quarterly Revenue Growth (YoY) | 7.20% |
| Shares Outstanding | $452.14M |
| Float | $450.65M |
| % Insiders | 0.37% |
| % Institutions | 94.79% |
Volatility is currently expanding
GEHC's Allia Celeo launch expands its interventional imaging portfolio with AI-powered precision, flexible workflows and predictive service capabilities.
GE HealthCare raises its 2026 earnings outlook on strong Q3 results, but tariff risks, fourth-quarter growth concerns and margin pressures remain in focus.
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today introduced Allia™ Celeo,* a ceiling-mounted image guiding system, at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 conference in San Diego. Developed around the principle of smooth procedural flow and built for interventional suites that prioritize high patient throughput and versatility across many indications, Allia Celeo pairs an extra-wide-bore C-arm with intuitive user interface, an AI-powered image chain, and compatib.
Investors with an interest in Medical - Products stocks have likely encountered both GE HealthCare Technologies (GEHC) and Haemonetics (HAE). But which of these two stocks is more attractive to value investors?
GE HealthCare Technologies delivered strong 3Q26 results, with broad-based demand, 6.2% organic revenue growth, and meaningful margin expansion. Pharmaceutical Diagnostics and Flyrcado offer attractive growth, while the SOFIE acquisition should strengthen radiopharmaceutical capabilities and future revenue streams. Raised 2026 outlook: organic revenue growth to 4%, adjusted EPS to $4.95–$5.05, and free cash flow to at least $1.6 billion.
GE HealthCare Technologies NASDAQ: GEHC reported third-quarter 2026 revenue growth across all of its business segments, supported by demand in imaging and pharmaceutical diagnostics, improved execution in patient care products and margin expansion.
GE HealthCare Technologies Inc. (GEHC) Q3 2026 Earnings Call Transcript
GE HealthCare's Q3 earnings and revenues beat estimates on strong segment growth and higher margins, driving raised 2026 guidance as shares gain 8.3%.
GEHC heads into Q3 earnings with strong imaging demand and a record backlog, but PCS weakness, inflation and supply challenges could weigh on margins.
GE HealthCare expands its theranostics imaging push with five global collaborations to evaluate StarGuide GX, targeting advances in precision oncology and nuclear medicine.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GEHC and any ticker you trade — then tracks every position and per-strategy win rate.
